- Home
- RNXT vs GDTC Comparison
RNXT vs GDTC Comparison
Compare RNXT & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- GDTC
- Stock Information
- Founded
- RNXT 2012
- GDTC 2018
- Country
- RNXT United States
- GDTC Singapore
- Employees
- RNXT N/A
- GDTC N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- RNXT Health Care
- GDTC Health Care
- Exchange
- RNXT Nasdaq
- GDTC Nasdaq
- Market Cap
- RNXT 30.0M
- GDTC 33.4M
- IPO Year
- RNXT 2021
- GDTC 2023
- Fundamental
- Price
- RNXT $1.27
- GDTC $2.37
- Analyst Decision
- RNXT Strong Buy
- GDTC Buy
- Analyst Count
- RNXT 2
- GDTC 1
- Target Price
- RNXT $6.50
- GDTC $5.00
- AVG Volume (30 Days)
- RNXT 118.6K
- GDTC 24.9K
- Earning Date
- RNXT 11-13-2024
- GDTC 01-01-0001
- Dividend Yield
- RNXT N/A
- GDTC N/A
- EPS Growth
- RNXT N/A
- GDTC N/A
- EPS
- RNXT N/A
- GDTC N/A
- Revenue
- RNXT N/A
- GDTC $330,254.00
- Revenue This Year
- RNXT N/A
- GDTC $14.71
- Revenue Next Year
- RNXT N/A
- GDTC N/A
- P/E Ratio
- RNXT N/A
- GDTC N/A
- Revenue Growth
- RNXT N/A
- GDTC N/A
- 52 Week Low
- RNXT $0.68
- GDTC $1.20
- 52 Week High
- RNXT $2.35
- GDTC $5.50
- Technical
- Relative Strength Index (RSI)
- RNXT 52.77
- GDTC 45.29
- Support Level
- RNXT $1.21
- GDTC $2.43
- Resistance Level
- RNXT $1.55
- GDTC $3.00
- Average True Range (ATR)
- RNXT 0.12
- GDTC 0.41
- MACD
- RNXT -0.02
- GDTC -0.03
- Stochastic Oscillator
- RNXT 32.20
- GDTC 21.60
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.